Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognized in the industry and by regulators as suitable for high yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production. CHOSOURCE has been utilized in multiple successful Innovative New Drug (IND) filings.
Horizon is already a key supplier for research relating to COVID-19, ...
